GE HealthCare Technologies Inc. (GEHC) Key Metrics
GEHC valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $31.42B
- Enterprise value
- $38.31B
- P/E (TTM)
- 16.0 10-yr median 15.9
- Forward P/E
- 12.1
- PEG ratio
- 1.65
- Price / sales
- 1.5 10-yr median 1.8
- Price / book
- 2.7 10-yr median 3.9
- EV / EBITDA
- 10.4 10-yr median 11.5
- Dividend yield
- 0.23% $0.16 a year
- Beta
- 0.85
GEHC key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGEHC valuation Price multiples at each fiscal year-end price.
GEHC returns How much profit the business earns on the capital it uses.
GEHC per-share figures Results divided by the shares outstanding at year-end.
GEHC financial health Debt, liquidity and how easily interest is covered.
GEHC efficiency & capital use Working capital cycle and where the cash goes.
GEHC valuation history
GEHC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GEHC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GEHC cash returned to shareholders
GEHC price vs earnings per share
GEHC key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $37.75B | $35.88B | $35.41B | $26.50B | — | — | — |
| Enterprise value | $43.24B | $42.37B | $42.77B | $33.69B | — | — | — |
| P/E ratio | 18.1 | 18.0 | 11.4 | 13.8 | — | — | — |
| Price / sales | 1.8 | 1.8 | 1.8 | 1.4 | — | — | — |
| Price / book | 3.6 | 4.2 | 5.0 | 2.8 | — | — | — |
| Price / free cash flow | 25.1 | 23.2 | 20.7 | 14.7 | — | — | — |
| Price / operating cash flow | 19.0 | 18.4 | 16.9 | 12.5 | — | — | — |
| EV / sales | 2.1 | 2.2 | 2.2 | 1.8 | — | — | — |
| EV / EBITDA | 11.4 | 11.6 | 17.6 | 10.6 | — | — | — |
| EV / free cash flow | 28.7 | 27.3 | 25.0 | 18.7 | — | — | — |
| Earnings yield | 5.5% | 5.6% | 8.8% | 7.2% | — | — | — |
| Free cash flow yield | 4.0% | 4.3% | 4.8% | 6.8% | — | — | — |
| Dividend yield | 0.2% | 0.2% | 0.1% | 0.0% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.7% | 0.2% | 0.1% | 0.0% | — | — | — |
| Share price at fiscal year-end | $82.02 | $78.18 | $77.32 | $58.38 | — | — | — |
| Per share | |||||||
| Revenue per share | $44.81 | $42.86 | $42.69 | $40.41 | $38.67 | $37.75 | $36.58 |
| Earnings per share | $4.53 | $4.34 | $6.78 | $4.22 | $4.94 | $30.45 | $3.35 |
| Operating cash flow per share | $4.32 | $4.25 | $4.59 | $4.65 | $3.53 | $3.71 | $4.37 |
| Free cash flow per share | $3.27 | $3.38 | $3.74 | $3.97 | $2.99 | $3.14 | $3.65 |
| Cash per share | $9.80 | $6.30 | $5.47 | $3.18 | $1.22 | $2.21 | — |
| Book value per share | $22.55 | $18.40 | $15.57 | $20.61 | $36.63 | $32.39 | — |
| Tangible book value per share | −$9.21 | −$12.56 | −$15.41 | −$10.96 | $4.21 | $2.76 | — |
| Dividends per share | $0.14 | $0.12 | $0.09 | $0.00 | $0.00 | — | — |
| Capex per share | $1.05 | $0.87 | $0.84 | $0.68 | $0.55 | $0.57 | $0.73 |
| Debt per share | $21.73 | $20.43 | $21.53 | $19.02 | $0.96 | $1.03 | — |
| Shares outstanding | 460.3M | 459.0M | 458.0M | 453.9M | 454.7M | 454.7M | 454.7M |
| Change in shares outstanding | +0.3% | +0.2% | +0.9% | −0.2% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | 22.1% | 25.6% | 37.6% | 14.7% | 14.3% | 94.0% | — |
| Return on invested capital (ROIC) | 14.0% | 14.2% | 15.7% | 11.8% | 14.4% | 14.6% | — |
| Return on assets (ROA) | 6.0% | 6.1% | 10.3% | 7.1% | 8.9% | 57.1% | — |
| Return on tangible assets | 9.4% | 10.6% | 17.0% | 14.5% | 19.4% | 128.7% | — |
| Free cash flow margin | 7.3% | 7.9% | 8.8% | 9.8% | 7.7% | 8.3% | 10.0% |
| Income quality (OCF / net income) | 0.95 | 0.98 | 0.68 | 1.10 | 0.72 | 0.12 | 1.31 |
| Financial health | |||||||
| Total debt | $10.00B | $9.38B | $9.86B | $8.63B | $437.0M | $468.0M | — |
| Cash & short-term investments | $4.51B | $2.89B | $2.50B | $1.45B | $556.0M | $1.01B | — |
| Net debt | $5.49B | $6.49B | $7.36B | $7.19B | −$119.0M | −$539.0M | — |
| Debt / equity | 0.96 | 1.11 | 1.38 | 0.92 | 0.03 | 0.03 | — |
| Debt / assets | 0.27 | 0.28 | 0.30 | 0.31 | 0.02 | 0.02 | — |
| Net debt / EBITDA | 1.45 | 1.77 | 3.02 | 2.27 | −0.03 | −0.16 | — |
| Current ratio | 1.18 | 1.00 | 1.00 | 1.09 | 0.97 | 0.84 | — |
| Quick ratio | 0.93 | 0.79 | 0.78 | 0.79 | 0.68 | 0.59 | — |
| Interest coverage | 6.1 | 5.2 | 4.5 | 29.3 | 69.9 | 41.2 | 24.1 |
| Working capital | $1.60B | −$37.0M | $29.0M | $628.0M | −$218.0M | −$1.08B | — |
| Invested capital | $15.87B | $14.93B | $14.49B | $16.55B | $16.54B | $14.19B | — |
| Tangible asset value | −$4.02B | −$5.56B | −$6.88B | −$4.74B | $2.16B | $1.50B | — |
| Net current asset value | −$15.61B | −$14.92B | −$16.13B | −$10.13B | −$2.87B | −$3.81B | — |
| Graham number | $47.93 | $42.40 | $48.73 | $44.25 | $63.82 | $148.96 | — |
| Graham net-net per share | −$38.48 | −$37.68 | −$40.23 | −$27.38 | −$11.08 | −$12.00 | — |
| Capital allocation | |||||||
| Dividends paid | $64.0M | $55.0M | $41.0M | $0 | $0 | — | — |
| Share buybacks (net) | $200.0M | $0 | $0 | — | — | — | — |
| Dividend payout ratio | 3.1% | 2.8% | 1.3% | 0.0% | 0.0% | — | — |
| Dividends + buybacks / free cash flow | 17.5% | 3.5% | 2.4% | 0.0% | 0.0% | — | — |
| Capex / revenue | 2.3% | 2.0% | 2.0% | 1.7% | 1.4% | 1.5% | 2.0% |
| Capex / operating cash flow | 24.2% | 20.6% | 18.4% | 14.7% | 15.4% | 15.4% | 16.6% |
| Capex / depreciation | 0.83 | 0.69 | 0.63 | 0.49 | 0.40 | 0.41 | 0.50 |
| Stock-based compensation / revenue | 0.6% | 0.6% | 0.6% | 0.4% | 0.4% | −5.4% | 0.9% |
| R&D / revenue | 6.1% | 6.7% | 6.2% | 5.6% | 4.6% | 4.7% | 5.0% |
| SG&A / revenue | 20.1% | 21.7% | 21.9% | 19.8% | 20.3% | 18.9% | 21.6% |
| Efficiency | |||||||
| Days sales outstanding | 73.7 | 80.6 | 77.5 | 77.5 | 66.9 | 56.5 | — |
| Days of inventory on hand | 61.5 | 62.1 | 64.6 | 67.1 | 62.1 | 56.0 | — |
| Days payables outstanding | 92.5 | 95.0 | 94.7 | 95.1 | 89.7 | 83.8 | — |
| Cash conversion cycle (days) | 42.8 | 47.7 | 47.4 | 49.4 | 39.3 | 28.7 | — |
| Receivables turnover | 4.95 | 4.53 | 4.71 | 4.71 | 5.45 | 6.46 | — |
| Payables turnover | 3.95 | 3.84 | 3.85 | 3.84 | 4.07 | 4.36 | — |
| Inventory turnover | 5.93 | 5.88 | 5.65 | 5.44 | 5.88 | 6.52 | — |
| Asset turnover | 0.59 | 0.60 | 0.65 | 0.68 | 0.70 | 0.71 | — |
| Average receivables | $4.17B | $4.35B | $4.15B | $3.89B | $3.22B | $2.66B | — |
| Average payables | $3.14B | $2.98B | $3.02B | $2.91B | $2.56B | $2.39B | — |
| Average inventory | $2.09B | $1.95B | $2.06B | $2.05B | $1.77B | $1.59B | — |
| Intangibles / total assets | 39.6% | 43.0% | 43.7% | 52.0% | 56.0% | 55.6% | — |
Computed from GEHC's annual financial statements (latest annual report filed February 4, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GEHC valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), GE HealthCare traded at 18.1 times earnings, against a 7-year median of 15.9. Based on the latest twelve months, the trailing P/E is 16.0 and the forward P/E is 12.1. GE HealthCare earned a return on equity of 22.1% and a return on invested capital of 14.0% in fiscal 2025. It ended the year with $10.0 billion of debt and $4.5 billion in cash and short-term investments, net debt of $5.5 billion. It returned $264.0 million to shareholders: $64.0 million in dividends and $200.0 million in share buybacks, 18% of free cash flow.
See the GEHC income statement, the GEHC chart for price history, or the GEHC stock overview for the latest quote and news.
GEHC key metrics FAQ
What is GE HealthCare's P/E ratio?
GE HealthCare's trailing P/E ratio is 16.0 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 12.1. At the end of fiscal 2025 it was 18.1, compared with a 7-year median of 15.9.
What is GE HealthCare's EV/EBITDA?
GE HealthCare's enterprise value was 11.4 times EBITDA at the end of fiscal 2025 (enterprise value $43.2 billion, EBITDA $3.8 billion); the current EV/EBITDA is 10.4.
What is GE HealthCare's return on equity?
GE HealthCare's return on equity (ROE) was 22.1% in fiscal 2025: net income of $2.1 billion on average shareholders' equity of $9.4 billion.
What is GE HealthCare's ROIC?
GE HealthCare's return on invested capital was 14.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does GE HealthCare have?
GE HealthCare had total debt of $10.0 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.96 and $5.5 billion of net debt (1.45 times EBITDA).
What is GE HealthCare's dividend yield?
GE HealthCare's forward dividend yield is 0.23%. GE HealthCare paid $64.0 million in dividends in fiscal 2025 ($0.14 per share), a payout ratio of 3.1%.
Does GE HealthCare buy back its shares?
Yes. GE HealthCare spent $200.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.3% over the year, to 460.3M..
What is GE HealthCare's free cash flow yield?
GE HealthCare generated $1.5 billion of free cash flow in fiscal 2025, a free cash flow yield of 4.0% on its market value at year-end ($37.8 billion).
What is GE HealthCare's current ratio?
GE HealthCare's current ratio was 1.18 at the end of fiscal 2025: current assets were 1.18 times current liabilities.